ArticleBMC cancer2026
Development and external validation of multiple machine learning-based models for breast cancer-specific survival prediction in postoperative patients with invasive breast cancer: a study based on the SEER database and an external cohort.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPatients with invasive breast cancer (IBC) make up most breast cancer cases and exhibit significant heterogeneity. Therefore, it is essential to construct an effective model to estimate long-term postoperative breast cancer-specific survival (BCSS).
methodsWe used data from the Surveillance, Epidemiology, and End Results (SEER) database during 2010-2020, alongside recruiting an external cohort from Guangxi Medical University Cancer Hospital (GMUCH). We constructed four prediction models (Random Survival Forest [RSF], Survival Gradient Boosting Machine [Survival-GBM], Survival Extreme Gradient Boosting [Survival-XGBoost], and Least Absolute Shrinkage and Selection Operator-Cox proportional hazards model [LASSO-Cox]) to predict 3-, 5-, 7-, and 10-year BCSS in patients with IBC.
resultsThe RSF model developed in this study exhibited outstanding predictive performance, with a C-index of 0.824 (95% CI: 0.817-0.831) in the training set, 0.689 (95% CI: 0.670-0.707) in the internal validation set, and 0.716 (95% CI: 0.649-0.772) in the external validation set-outperforming its counterparts. Time-dependent Brier scores confirmed the model's excellent calibration and high predictive accuracy. Decision curve analysis (DCA) further confirmed the model's stable clinical utility, while Shapley Additive Explanations (SHAP) diagrams quantified the importance of prognostic features. Additionally, the RSF model demonstrated strong efficacy in stratifying patients into distinct BCSS risk subgroups.
conclusionsIn conclusion, this study developed an optimal prognostic model for predicting the long-term BCSS of IBC patients, which provides critical support for risk stratification in the clinical management of IBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.